Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$37.66 USD

37.66
184,435

+0.09 (0.24%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $37.66 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Integra's (IART) Margin Pressure Hurts, Global Prospects High

by Zacks Equity Research

Massive gross margin declines induced by mounting costs are a major downside for Integra LifeSciences (IART).

Here's Why You Should Buy Thermo Fisher (TMO) Stock Now

by Zacks Equity Research

Thermo Fisher (TMO) gains on strength in all end markets. It witnesses consistent growth in the Asia-Pacific and emerging markets.

Quest Diagnostics to Buy Laboratory Services Unit in Midwest

by Zacks Equity Research

Quest Diagnostics (DGX) continues to expand inorganically. The latest buyout is expected to expand the company's portfolio in the Midwest.

CVS Health (CVS) Gets Final Approval to Close Aetna Deal

by Zacks Equity Research

Both CVS Health (CVS) and Aetna are hopeful about this consolidation, which is aimed at revolutionizing consumer health care experience and substantial cost reduction.

Medtronic (MDT) Positive on Mazor Purchase, Rising Costs Ail

by Zacks Equity Research

The pending acquisition of Mazor Robotics holds great potential as it is likely to solidify Medtronic's (MDT) position in robotic spine surgery.

Align Technology's New iTero Scanner Updates to Boost Uptake

by Zacks Equity Research

Align Technology (ALGN) adopts initiatives to boost top-line contributions from iTero Intraoral scanners.

Edwards Lifesciences' Critical Care Arm Solid, THVT View Dull

by Zacks Equity Research

Edwards Lifesciences (EW) sees strong Critical Care division sales. Management expects sluggish underlying THVT sales for 2018.

Here's Why You Should Invest in Merit Medical (MMSI) Now

by Zacks Equity Research

A strong outlook for 2018 and a solid global foothold make Merit Medical (MMSI) a promising investment pick.

Here's Why You Should Invest in Abiomed (ABMD) Right Now

by Zacks Equity Research

Abiomed (ABMD) continues to gain from its flagship Impella; a strong fiscal 2019 outlook encourages.

Here's Why You Should Invest in Hill-Rom (HRC) Stock Now

by Zacks Equity Research

Hill-Rom (HRC) focuses on product innovation. Through fiscal 2018, new products generated more than $300 million in revenues.

RTI Surgical Gains From HealthPartners' Nod for SI Surgery

by Zacks Equity Research

RTI Surgical's (RTIX) minimally invasive SImmetry System sees lucrative market prospects for the stock's growth.

Here's Why You Should Buy Intuitive Surgical (ISRG) Now

by Zacks Equity Research

Strength in the surgical platform and an upbeat view for 2018 make Intuitive Surgical (ISRG) a promising pick.

Express Scripts & Petco Tie Up, Ease Access to Pet Medicines

by Zacks Equity Research

Express Scripts' (ESRX) Inside Rx Pets discount card is likely to make pet medicines affordable.

Are WMGI & ARAY Neck and Neck? Let's Take a Closer Look

by Zacks Equity Research

Wright Medical (WMGI) scores higher than Accuray (ARAY) when it comes to current-year earnings and growth projections.

Surmodics Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Surmodics has been struggling lately, but the selling pressure may be coming to an end soon.

Medidata's Cloud Platform Picked by China's Hengrui, Stock Up

by Zacks Equity Research

Medidata's (MDSO) cloud-based platform sees immense prospects in APAC.

Surmodics' (SRDX) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Surmodics (SRDX) sees solid segmental performance in fiscal Q4; gains from alliance with Abbott.

SurModics (SRDX) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 600.00% and 2.21%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate SurModics (SRDX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wright Medical (WMGI) Takes Over Cartiva for $435M in Cash

by Zacks Equity Research

The Cartiva buyout will boost Wright Medical's (WMGI) Lower Extremities business.

Express Scripts Introduces Medicare PDP Offerings for 2019

by Zacks Equity Research

Express Scripts' (ESRX) Medicare PDP to initiate coverage from Jan 1, 2019. The plan includes Walmart along with CVS Pharmacy and the Kroger Family of Pharmacies.

Here's Why You Should Hold Ecolab Stock in Your Portfolio

by Zacks Equity Research

Despite fluctuations in the cost of raw materials, Ecolab (ECL) to gain from strong performance in the Global Industrial segment.

    AtriCure (ATRC) Looks Good: Stock Adds 6.8% in Session

    by Zacks Equity Research

    AtriCure (ATRC) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

    Zacks.com highlights: Lululemon Athletica, Malibu Boats, Surmodics and Baxter International

    by Zacks Equity Research

    Zacks.com highlights: Lululemon Athletica, Malibu Boats, Surmodics and Baxter International

      Here's Why You Should Hold Medidata Stock in Your Portfolio

      by Zacks Equity Research

      Medidata's (MDSO) Clinical Cloud platform is likely to provide it a competitive edge in the MedTech space. However, cutthroat competition in the niche space is a headwind.